application of biopharmaceutics classification system in formulation developments
TRANSCRIPT
![Page 1: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/1.jpg)
Application of Biopharmaceutics Classification System in Formulation Developments
Ideas for Today and Tomorrow
Surang JudistprasertBio-innova & Synchron co.,ltd.
![Page 2: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/2.jpg)
Biopharmaceutics Classification System
Drug Products
Solubility Permeability
Class I High* HighClass II** Low HighClass III High* LowClass IV Low Low
* Highly-soluble substance in a rapidly-dissolving formulation ** If Do Low ~ Highest probability of In vitro / in vivo correlation
![Page 3: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/3.jpg)
How to evaluate BCS drug?• Class I – No 1st Pass ~
Bioequivalent
• Class III & Class I + 1st Pass ~ Bioequivalent if Powered Properly
• Class II ~ Bioequivalent if dissolution data match at pH 1, pH 4.5, Ph 6.8 (If 1st pass ~ Power Properly)
• Class IV ~ Less predictable
![Page 4: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/4.jpg)
Class I - No significant first passBA ~ Hightmax ~ Short BE ~ Product is rarely a concern
◦ Rapidly Dissolving (Single point dissolution test)8 Dissolve immediately in the stomach8 Do not precipitate in the duodenum
BE ~ Study is rarely a concern◦ High permeability (Low Variability)
No resistance at the GI membrane
BCS Guidance ~ BE Waiver
![Page 5: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/5.jpg)
Class I – Significant 1st PassBA ~ Lower tmax ~ ShortBE ~ Product is rarely a concern
◦ Rapidly Dissolving (Single point dissolution test)8 Dissolve immediately in the stomach8 Do not precipitate in the duodenum
BE ~ Study can be a concern◦ Permeability high but 1st pass effect
Variability8 Variability (CVanova) can range from moderate to
high
BCS Guidance ~ BE Waiver
![Page 6: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/6.jpg)
Class II - No significant 1st Pass
BA & tmax = f (dissolution) BE ~ Product can be a concern (Do ?)
◦ Slowly Dissolving (Dissolution profile)8 Match dissolution profiles at pH 1, pH 4.5, & pH
6.88 If Do Low ~ Dissolution predicts PK (BE) ~ IVIVC
probable8 Variability can be due to product (RSD)
BE ~ Study is rarely a concern◦ High permeability (Low Variability)
![Page 7: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/7.jpg)
Class II - Significant 1st Pass
BA & tmax = f (dissolution) but BA will be Lower
BE ~ Product can be a concern◦ Slowly Dissolving (Dissolution profile)
8 Match dissolution profiles at lower pH8 Variability can be due to product (RSD)
BE ~ Study can be a concern◦ Permeability high but 1st pass effect
Variability Variability (CVanova) can range from moderate to
high
![Page 8: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/8.jpg)
Class III – with& without Significant 1st Pass
BA & tmax ~ Less predictableProduct is rarely a concern
◦ Rapidly Dissolving (Single point dissolution test)8 Dissolves immediately in the stomach8 Does not precipitate in the duodenum
BE Study can be a concern◦ Low Permeability Variability
8 Variability increases as g.i. permeability decreases
8 CVanova can range from moderate to high8 1st pass effect can add significantly to
variability
![Page 9: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/9.jpg)
Class IV – with and without significant 1st Pass
BA & tmax ~ Less predictableProduct can be a concern
◦ Slowly Dissolving (Dissolution profile)8 Match dissolution profiles at Lower pH (if soluble)8 Variability can be due to product (RSD)
BE Study can be a concern◦ Low Permeability Variability
8 Variability increases as g.i. permeability decreases
8 CVanova can range from moderate to high8 1st pass effect can add significantly to
variability
![Page 10: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/10.jpg)
Potential Impact of Failed BE Testing
Phase I◦ Food Effects◦ Dose Proportionality◦ Dose dumping from CR tablet broken at the
score◦ Drug-Drug Interactions
BE Studies SUPAC Site Transfers ANDA (Pilot & Pivotal BE Studies)
![Page 11: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/11.jpg)
When could the system break down ?
s2 of disposition > s2 of inputClass II - Insoluble under specified
dissolution conditions
[pH 1.0, 4.5, 6.8]Class III - If excipient alters
g.i. permeabilityClass I with 1st pass - If excipient alters
1st pass metabolism
![Page 12: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/12.jpg)
Designing a Successful BE Studyusing the BCSHypothesis Based upon Experience
Class I drug products are bioequivalent First Pass Metabolism ~ Variability ~ Design Issues
Certain excipients might alter g.i. permeability (???)
Guidance permits BE waiver
Class II drug products are usually bioequivalent if dissolution profiles match (pH 1, pH 4.5, pH 6.8)
◦ If first Pass Metabolism ~ Variability ~ Design Issues
◦ Certain excipients might alter g.i. permeability (???)
◦ Class II drugs that employ surfactant ?
![Page 13: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/13.jpg)
![Page 14: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/14.jpg)
Dissolution Testing is what links the dosage form to the proven efficacy (eg: typically the clinical lot used in the Phase 3 pivotal efficacy study)!
Dissolution testing is what links every lot of the dosage form from every manufacturer to the labeling (proven efficacy and safety)! This can be 100s or 1000s of lots separated by years or decades as well as continents from the pivotal efficacy lot.
![Page 15: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/15.jpg)
What have we learned about human physiology that might related to dissolution testing?
![Page 16: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/16.jpg)
Physiology: What volume of liquid is the dosage form exposed to?
![Page 17: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/17.jpg)
In-vivo Intestinal Fluid Flow Rates
Gutzeit A, Patak MA, Weymarn Cv, Graf N, Doert A, Willemse E, Binkert CA, Froehlich JM 2010. Feasibility of Small Bowel Flow Rate Measurement With MRI. Journal of Magnetic Resonance Imaging 32:345-351.
![Page 18: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/18.jpg)
Hydrodynamics of dissolution apparatus: USP Apparatus 2 - Velocity & Shear Profiles
• Highest velocities occur at the tip of the paddle (~20 cm/sec)
• The lowest velocities are directly beneath the centerline of the impeller and around the shaft of the impeller.
The shear rates throughout the vessel are heterogeneous. Maximum shear rates: 92s-1 at 50 RPM Average shear rates: ~ 20s-1 at 50 RPM
Ref: Bai G, Wang Y, Armenante PM 2011. Velocity Profiles and Shear Strain Rate Variability in the USP Dissolution Testing Apparatus 2 at Different Impeller Agitation Speeds. International Journal of Pharmaceutics 403:1-14.
![Page 19: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/19.jpg)
Physiology is complex
So - compendia! dissolution testing in 900 ml with a paddle (or rotating basket) doesn't really capture it.
![Page 20: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/20.jpg)
Importance of physical chemistry and physiologic buffer
Drug properties◦Solubility◦pKa◦Diffusion coefficient
◦Particle size
• Physiological properties• pH• Buffer species
and concentration
• Fluid hydrodynamics
• Intestinal mobility
• Bulk concentrations
• Volume and temperature
![Page 21: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/21.jpg)
Our Increasing Expectations in Drug Dissolution/Release Testing
Provide basic criteria for drug release from the product
For batch to batch consistency/quality (product specification)
As potential surrogate for in vivo BE studies
For linking the product and its in vivo performance (correlations or relationships: IVIVC or IVIVR)
![Page 22: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/22.jpg)
Recommendations from Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms (August 1997) An aqueous medium‐ pH range 1.2 to 6.8
(ionic strength of buffers the same as in USP)
To simulate gastric fluid (SGF), a dissolution medium of pH 1.2 (without enzymes)
The need for enzymes in SGF and SIF should be evaluated on a case‐by‐case basis and should be justified.
To simulate intestinal fluid (SIF), a dissolution medium of pH 6.8 should be employed (also, recommended for testing of ER products).
A higher pH should be justified on a case‐by‐case basis and, in general, should not exceed pH 8.0
![Page 23: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/23.jpg)
Recommendations for Dissolution Medium (Continued)
With gelatin capsule products– medium containing enzymes (pepsin with SGF and pancreatin with SIF) may be used to dissolve pellicles.
Use of water alone as a dissolution medium is discouraged (water source may affect test conditions such as pH and surface tension, and may change during the dissolution test ‐ due to the influence of the active and inactive ingredients)
For water insoluble or sparingly water soluble drug products, use of a surfactant such as sodium lauryl sulfate is recommended (Shah 1989, 1995). The need for and the amount of the surfactant should be justified.
![Page 24: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/24.jpg)
A Short List of Dissolution Media
![Page 25: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/25.jpg)
Composition of FaSSGF and FeSSGF
![Page 26: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/26.jpg)
Case study……
![Page 27: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/27.jpg)
ConclusionThere are many tools related to
dissolution that can aid in implementation of QbD ◦Biorelevant dissolution methods, which
may utilized advanced apparatus and/or media
◦ Predictive dissolution modeling IVIVC or IVIVR studies
All of these tools can aid product quality ◦Enhanced product and process
understanding ◦Clinically relevant specifications
![Page 28: Application of biopharmaceutics classification system in formulation developments](https://reader030.vdocuments.mx/reader030/viewer/2022032700/55d30a92bb61eb3f468b458c/html5/thumbnails/28.jpg)